The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosis
- Institution
- University of Washington, WA
- Principal investigator
- Chetan Seshadri
- Funding
- $989K
- Duration
- 2020–2030
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY Several lines of evidence from human and animal studies have revealed the critical importance of T cells in conferring protective immunity to Mycobacterium tuberculosis (M.tb). However, we still do not know which M.tb antigens are targeted by the T cells that confer protection. This information is critical to developing new subunit vaccines that are more effective than Mycobacterium bovis bacille Calmette-Guérin (BCG), which is currently the only licensed vaccine for tuberculosis (TB). Classically, T cells are activated by foreign peptide antigens that are bound to highly polymorphic major histocompatibility molecules. Alternatively, mycobacterial cell wall lipids have conclusively been shown to activate human T cells when bound to non-polymorphic CD1 proteins on antigen-presenting cells. The CD1 system mediates protective T-cell responses in mouse models of autoimmunity, cancer, and infectious diseases. However, the lack of an appropriate animal model has impeded research into the importance of CD1-restricted T cells in the pathogenesis of M.tb. Tools to identify CD1- restricted T cells were also unavailable until recently. We have established lipid-loaded CD1 tetramers as tools to study the phenotypes and functions of CD1-restricted T cells in humans and non-human primates. We have also developed and validated a humanized CD1 transgenic (hCD1Tg) mouse model and shown that T-cells specific for mycolic acid, a major constituent of the mycobacterial cell wall, confer protective immunity to M.tb challenge. Finally, we have developed a lipid-based nanoparticle vaccine and shown that it induces durable T cell responses to mycolic acid in hCD1Tg mice. In Aim 1 of this renewal application, we will determine how lipid chain length, alveolar macrophages, and dendritic cells modulate T cell responses induced by nanoparticle vaccination. In Aim 2, we will use lipid-loaded tetramers to define the phenotypes and functions of CD1-restricted T cells in rhesus macaques after intravenous BCG vaccination, which confers sterilizing immunity to M.tb challenge. We will also use quantitative PCR to enumerate CD1-restricted T cells in pulmonary granulomas and correlate this with bacterial burden. In Aim 3, we will determine the role of CD1-restricted T cells in mediating control of M.tb infection in hCD1Tg mice using adoptive transfer of transgenic T cells as well as a BCG prime and nanoparticle boosting vaccine regimen. Finally, we will leverage a tonsil organoid model of human tuberculosis to determine whether human CD1-restricted T cells are activated and express anti-bacterial effector functions after M.tb infection as well as control bacterial replication. By the end of the funding period, we will have defined the role of CD1-restricted in M.tb pathogenesis and provided the rationale for whether lipid-specific T cells should be considered a correlate of protective immunity in ongoing Phase II/III clinical efficacy studies of whole cell mycobacterial vaccines.
LOADING MOONBASE SCORE
Questions for University of Washington
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of WashingtonNot yet scored
Seattle Tuberculosis Research Advancement Center
Rhea N Coler · $1.0M · 2022–2027
- NIH · University of WashingtonNot yet scored
Administrative Core
Chetan Seshadri · $346K · 2022–2027
- NIH · University of WashingtonNot yet scored
Core-004
Rhea N Coler · $177K · 2022–2027